Insider trades
Keith Regnante, CFO of Keros Therapeutics KROS, has filed 0 purchases and 8 sales on the open market. Over the past 12 months that comes to a net sale of $77.5K. The latest trade was on 02/24.
Keith Regnante
CFO
- Company
- Keros Therapeutics KROS
- First filing
- 23/02/17
- Trades
- 19 trades
- Buys / sales
- 0 / 8
- 12-month net buying
- −$77.5K
- Last trade
- 02/24
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
| Open-market sale | 02/18 | 02/20 | 4,739 sh | $16.35 | $77,482.65 | −10.8% | |
| Open-market saleAmendment | 24/01/04 | 25/01/24 | 40,000 sh | $45.29 | $1,811,600 | −100.0% | |
| Open-market sale | 23/11/04 | 24/01/08 | 40,000 sh | $45.29 | $1,811,600 | −100.0% | |
KROS | Open-market sale10b5-1 plan | 23/06/08–23/06/09 | 23/06/12 | 40,000 sh5 trades | $46.61avg. | $1,864,239.43 | −100.0% |